WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 13, 430-438. Review Article ISSN 2277–7105

TRANSDERMAL PATCHES FOR SUSTAINED RELEASE OF ANTI-INFLAMMATORY DRUGS

Rajan Chaudhary[1]* and Dr. N. Trilochana[2]

[1*]Research Scholar, Department of Pharmaceutics,
Professor Department of Pharmacology,
Saroj Institute of Technology and Management, Lucknow, 226002.

Article Received on
12 May 2025,
Revised on 01 June 2025,
Accepted on 21 June 2025,
DOI: 10.20959/wjpr202513-37375

***Corresponding Author**
Rajan Chaudhary
Research Scholar, Department of Pharmaceutics, Saroj Institute of Technology and Management, Lucknow, 226002.

ABSTRACT

Transdermal drug delivery systems (TDDS) offer a promising alternative for the sustained release of anti-inflammatory drugs, enhancing therapeutic efficacy while minimizing systemic side effects. This study focuses on the formulation, development, and evaluation of transdermal patches designed for the controlled release of selected non-steroidal anti-inflammatory drugs (NSAIDs). The rationale behind utilizing transdermal patches lies in their ability to bypass first-pass metabolism, maintain consistent plasma drug concentrations, and improve patient compliance. Various polymers such as hydroxypropyl methylcellulose (HPMC), ethyl cellulose (EC), and polyvinyl alcohol (PVA) were employed as matrix formers, while permeation enhancers were incorporated to facilitate drug transport across the skin barrier. The patches were subjected to physicochemical characterization, in vitro drug release studies, and skin permeation tests to assess their performance. Results indicated a sustained release profile over 24 hours, with optimal mechanical properties and bio adhesive strength. These findings support the potential of transdermal patches as an effective platform for the prolonged delivery of anti-inflammatory agents in the management of chronic inflammatory conditions.

KEYWORDS: Transdermal drug delivery systems, Anti-inflammatory drugs, Non-Steroidal Anti-Inflammatory Drugs.

1. INTRODUCTION

1.1. NOVEL DRUG DELIVERY SYSTEM

This century has fully fledged varied exceptional developments in progressive consciousness within the facade of budding associate that medication is extremely deadly and sometimes ineffective, once administered or applied by conventional way. Thus, usually administered drug formulations like tablets, capsules, oral liquids and injections that are directed as multi-doses sometimes produce massive variation of drug concentration within the blood stream. The developing price of a brand-new drug will be around $250 million (Rs. 900 crores) and income pertaining to 12-15 years to unfold within the market. This technology is pertinent to many kinds of medicine agents and applicable to therapeutic situations, like cardiovascular disease, asthma, arrhythmias, diabetes, fertility management, organic process ulcers, rheumatism, cardiopathy, cancer, depression, biological time syndrome etc. newer drug delivery systems symbolize pharmacologically active moiety will be ceaselessly delivered either to a target website or systemically in a good, consistent and harmless manner. They are capable of higher performance than typical delivery by watching the concentration, location and length of drug action.

1.2. DEVELOPMENT IN TRANSDERMAL DRUG DELIVERY

At the flip of the span, throughout war II, munitions staff old fewer anginas' attacks whereas operating with vasodilative. This has challenged the standard belief that the skin may be an excellent protecting barrier and conjointly triggered intensive analysis activities to check the practicableness for general medication. Several transdermal drug delivery systems (TDDS) are recently development with the intention of achieving the target of general medication through the transdermal controlled delivery of prescribed drugs. The utilization of TDDS was initially explained by the effective growth of a hyoscine cathartic TDD system in 1981 (Transderm- Scop system, Ciba) for 72-hour bar or treatment of motion elicited illness and nausea, then by the selling action of many vasodilative cathartic TDD systems of once every day medication of angina. Furthermore, toward the marketed formulation, novel formulation is produced. Buspar, an agent to stop anxiety and therefore the mixture of phytotoxin and mecamylmine, for smoking surcease medical aid are being developed for TDDS and are at this time undergoing clinical test/clinical trials.

Inflammation is a complex biological response to harmful stimuli, often treated with non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Oral administration of these

drugs can lead to systemic side effects. Transdermal patches present a novel strategy for delivering anti-inflammatory drugs directly into systemic circulation, minimizing adverse effects and improving therapeutic efficacy.

2. Advantages of Transdermal Drug Delivery Systems

- Bypasses gastrointestinal tract and first-pass hepatic metabolism
- Provides controlled and sustained drug release
- Enhances patient compliance due to ease of use
- Reduces dosing frequency and side effects
- Suitable for patients with swallowing difficulties

3. SKIN STRUCTURE AND PENETRATION ROUTES

The skin, particularly the stratum corneum, acts as the main barrier to drug permeation. The drug penetrates the skin via three primary routes.

3.1 Transcellular Route

- Drug passes directly through keratinocytes of the stratum corneum.
- Involves both lipid and aqueous domains.
- Suitable for small, lipophilic drugs.

3.2 Intercellular Route

- Drug diffuses around the cells through the lipid matrix.
- Main pathway for most transdermal drugs.
- Favoured by lipophilic and amphiphilic molecules.

3.3 Appendageal Route

- Involves penetration through hair follicles and sweat glands.
- Minor pathway (<1% of total skin surface area) but useful for larger molecules or hydrophilic drugs.

4. PENETRATION ENHANCERS

Penetration enhancers, also known as permeation enhancers or absorption promoters, are substances that facilitate the transport of drugs across the skin barrier, particularly the stratum corneum. The stratum corneum poses the most significant challenge to transdermal drug delivery due to its highly organized lipid matrix and keratinized cells. Enhancers act by

temporarily altering the skin's physicochemical properties without causing long-term damage or irritation.

MECHANISM OF ACTION

Penetration enhancers work via one or more of the following mechanisms:

- **Disruption of intercellular lipid structure**, increasing fluidity and permeability.
- **Interaction with keratin** in corneocytes to loosen tight protein structures.
- **Improvement in drug solubility** and partitioning into the skin.
- **Enhancement of drug diffusivity** by modifying skin hydration or polarity.

4.1 Alcohols

- Examples: Ethanol, isopropanol
- Disrupt lipid organization in the stratum corneum
- Improve solubility of drugs

4.2 Fatty Acids

- Examples: Oleic acid, linoleic acid
- Fluidize lipid bilayers, enhancing drug diffusion

4.3 Surfactants

- Examples: Sodium lauryl sulfate, polysorbates
- Interact with keratin and lipids to open tight junctions
- Increase hydration and permeability

5. FORMULATION ASPECTS

A typical transdermal patch comprises

- Drug reservoir: Contains the anti-inflammatory drug.
- Polymeric matrix: Controls drug release rate.
- Adhesive layer: Ensures skin contact.
- Backing membrane: Protects the patch from the external environment.
- Release liner: Removed before application.

6. ANTI-INFLAMMATORY DRUGS USED IN TRANSDERMAL PATCHES

Inflammation is one of the most significant and very complex experience. The international association for the study of pain (1986) has defined pain as

Nociception can be defined as response specific to potentially tissue damage stimulation. It is

mechanism wherein noxious peripheral stimuli are transmitted to the central nervous system. The recent evidence suggests that pain may be postulated.

The word Inflammation is commonly used in medicine and by the lay public, but when it is meaning is examined closely, difficulties of interpretation appear which in the past have been given rise to much discussion. The process of inflammation is the sequence of variations which happen in living tissues when it is bruised, provided that the injury is not of such a degree to destroy it is structure and vitality.

The important idea to grasp at the outset is that inflammation is a process and not a state. Fortunately, it has proved possible to devise means by which the successive macroscopically and microscopically changes of inflammation can be watched in great detail in the living animal **Florey (1964)**. Inflammation is a sequence of pathological changes linked with local vascular reaction and cellular response, of the living tissue, to an injury, insufficient to kill the tissues. This is differentiated from

Commonly delivered drugs include

- NSAIDs: Diclofenac, Ketoprofen, Ibuprofen
- Corticosteroids: Dexamethasone, Hydrocortisone

  These drugs are selected based on their molecular weight (<500 Da), lipophilicity (log P 1–3), and potency at low doses.

7. EVALUATION PARAMETERS

Currently, tremendous analysis is going on in the evaluation of the objective of this research to seek out correlation between the percutaneous absorption and laboratory results (*in-vitro*) experienced by living subjects, so that in-vivo experimentation may be curtailed. There is no extensive data offered in the writing on the in-vitro dissolution methodology, for percutaneous patches. The various manufactures of percutaneous patches use completely different dissolution strategies from the point of view of quality assurance needs. There is a precise need for the development and implementation of a single, most likely universal, dissolution methodology to assure patch – to– patch uniform release. The aim of in- vitro experimentation in TDD is to know and/ or predict the delivery and penetration of a molecule from the skin surface into the body. Typically, this can be achieved by employing a form of skin diffusion cells and numerous experimental protocols. TDD are often represented in 3 principal stages for understanding in planning of appropriate in-vitro experiment**.**

Transdermal patches are evaluated for

- Drug content uniformity
- Adhesion properties
- In vitro drug release
- Skin permeation studies Stability studies.

8. FUTURE PROSPECTS

Advanced technologies such as microneedles, iontophoresis, sonophoresis, and nano-formulations are being developed to improve transdermal delivery of both small and large anti-inflammatory drugs.

9. CONCLUSION

Transdermal patches represent a promising and patient-friendly approach for the sustained release of anti-inflammatory drugs. Understanding the skin penetration mechanisms and optimizing the use of enhancers can significantly improve drug bioavailability. Continuous advancements in formulation science and skin biology are likely to expand the therapeutic applications of transdermal systems.

REFRENCES

1. Alasdair DT, *et al.* Pathology Illustrated. II edition, London, Churchill Livingstone; ISBN-10: 0443041679; 1988.
2. Anoop, M.V. and Bindu, A.R., 2015. In-vitro Anti-inflammatory Activity Studies on Syzygiumzeylanicum (L.) DC Leaves. *IJPRR*, *4*(8): 18-27.
3. Arora, P., Mukherjee, B., 2002. Design, development, physicochemical and invitro, in vivo evaluation of transdermal padses containing diclofenac diethyl ammonium salt, Journal of Pharmaceutical sciences, 91(9): 2078-2088.
4. Azab, A., Nassar, A. and Azab, A.N., 2016. Anti-inflammatory activity of natural products. *Molecules*, *21*(10): 1321.
5. Bachhav, R.S., Gulecha, V.S. and Upasani, C.D., 2009. Analgesic and anti- inflammatory activity of Argyreiaspeciosa root. *Indian journal of pharmacology*, *41*(4): 158.
6. Balasubramanian, A., Ramalingam, K., Krishnan, S. and Ajm, C., 2005. Anti-inflammatory activity of Morusindica Linn. *Iranian journal of Pharmacology and Therapeutics*, *4*(1): 13-0.
7. Barry, B. W. and Williams, A. C., Permeation Enhancement through skin in Encyclopedia of pharmaceutical Technology, Vol-11, Marcel Dekker Inc., Newyork, 1996; 449-493.

8. Bommannan, D., Okuyama, H., Staufer, P., Guy, R., Proceed. Intern. Symp. Contr. Rel. Bioact. Mater, 1990; 17: Abst. No. D104.
9. Chaudhary, B. and Verma, S., 2014. Preparation and evaluation of novel in situ gels containing acyclovir for the treatment of oral herpes simplex virus infections. *The Scientific World Journal*, *2014*; 280928: 1-7.
10. Chein, Y. W., Novel Drug Delivery System., Vol-14, Marcel Dekker Inc. publication., 1982; 191.
11. Dey NC and Dey TK. A Text Book of Pathology. IIIrd edition, Calcutta, Messrs Allied Agency;. **ISBN-13:** 9788173810619; 1970
12. Dhamane, S., 2017. Formulation and Evaluation of Novel Drug Delivery System for Treatment of Peptic Ulcer *Ijppr*. *Human*, 9(1): 121-140.
13. Dhiman, S., Singh, T.G. and Rehni, A.K., 2011. Transdermal patches: a recent approach to new drug delivery system. *Int J Pharm PharmSci*, *3*(5): 26-34.
14. Dimo, T., Fotio, A.L., Nguelefack, T.B., Asongalem, E.A. and Kamtchouing, P., 2006. Anti-inflammatory activity of leaf extracts of KalanchoecrenataAndr. *Indian Journal of Pharmacology*, *38*(2): 115.
15. Enscore, D.J. and Gale, R.M., U.S. patent, 1985; 4: 559,222.
16. Fakhrudin, N., Hastuti, S., Andriani, A., Widyarini, S. and Nurrochmad, A., 2015. Study on the anti-inflammatory activity of Artocarpusaltilis leaves extract in mice. *Int. J. Pharmacogn. Phytochem. Res.*, *7*: 1080-1085.
17. Florey HW. General pathology. IIIrd edition, London, Llyod-Luke (Medical Books) Ltd. 1964; **ISBN-10:** 085324054X
18. Flynn, G. L., Atewart, B., ―Percutaneous drug penetration, choosing candidates for transdermal development‖., Drug Dev Res., 1988; 13: 169- 185.
19. Godbey, K. J., Development of a novel transdermal drug delivery backing film with a low moisture vapour transmission rate, Pharm. Technol, 1997; 21(10): 98-107.
20. Good, W. R., Transder®-Nitro Controlled Delivery of Nitroglycerin via the Transdermal Route, Drug Development and Industrial Pharmacy, 1983; 9:4, 671-689. for the controlled delivery of drugs, Polym New, 1982; 8: 230-236.
21. Gupta, G.D. and Gaud, R.S., 2006. Anti-inflammatory activity of tenoxicam gel on carrageenan-induced paw oedema in rats. *Indian journal of pharmaceutical sciences, 2006; 68(3): 356-359.*
22. Guy, R. H., and Hadgraft, J., ―Selection of drug candidates for transdermal drug delivery in- transdermal drug delivery: developmental issues and research initiative‖; Marcel

Dekker; Inc. New York., 1989; 35: 60-72.

23. Hafeez, A., Jain, U., Sajwan, P., Srivastava, S. and Thakur, A., 2013. Evaluation of Carrageenan induced anti-inflammatory activity of ethanolic extract of bark of Ficusvirens Linn. inswiss albino mice. *J Phytopharmacol*, *2*: 39-43.
24. Harborne, J.B., *Phytochemical Methods*, 1st edition, Chapman and Hall, New York, ISBN-13, 1984; 978-0-412-23050-9.
25. Hardman. B. and Torkelson A., Silicones In, Encyclopedia of Polymer Science & Engineering, John Wiley & Sons, New York, 2nd edition, 1989; 204-308.
26. Hogson, M. E., Pressure sensitive adhesive and their application in adhesion 3 (K. W. Allened) Applied science, London, 1978; 207-220.
27. Hosaka, S., Ozawa, H. and Tanzawa.H., J., Controlled release of drugs from hydrogel matrices, Journal of Applied Polymer Science banner, 1979; 23(7): 2089-2098.
28. Hossain, M.S., Chowdhury, M.E.H., Das, S. and Chowdhury, I.U., In-Vitro Thrombolytic and Anti-inflammatory Activity of Swertia Chirata Ethanolic Extract. *Journal of Pharmacognosy and Phytochemistry*, 2012; *1*(4): ISSN 2278- 4136, 99-104.
29. Hurkmans, J. F. Bodde H. E., Van Driel, L. M., Vandoorne, J., and Juginger, H. E., ― skin irritation caused by transdermal drug delivery systems during long term application‖, Br J Dermatol., 1985; 112: 461-467.
30. Jahan, N., Afaque, S. H., Physico-chemical studies of the Gum Acacia, Natural Product Radiance. 2008; 7(4): 335-337.
31. Jahangir Mohammed Asadullah, Dr. Saleem MA, Shahab Mohammed Shadab, Muheem Abdul, Saleem Shakir, Formulation and evaluation of novel floating in situ gelling system of macrolide antibiotic using different gelling polymers. Journal of Drug Delivery & Therapeutics. 2015; 5(5): 48-55.
32. John, N.A.A. and Shobana, G., Anti-inflammatory activity of *Talinum fruticose* on formalin induced paw edema in albino rats, *Journal of applied pharmaceutical science*, 2012; *2*(1): 123.
33. Jonathan Hodgraft, Richard H. Guy, Transdermal Drug Delivery, 1989; ISBN 9780824708610, 293-311.
34. Kari, B., Control of blood glucose levels in alloxan diabeticrabbits by iontophoresis of Insulin, Diabetes, 1986; 35(2): 217-221.
35. Karimunnisa S, Puja P, Sangita K, Bothiraja C. Development and Evaluation of a Novel Drug Delivery System for Albendazole. Indian J of Pharmaceutical Education and Research. 2018; 52(3): 408-15.

36. Katz, M., and Poulsen, B. J., Absorption of drugs through the skin in Handbook of Experimental Pharmacology, Vol 28; Springer Verlag, New York., 1971, ISBN: 978-3-642-65054-3, 103-174.
37. Keith AD. Polymer matrix consideration for transdermal device, Drug Dev. Ind. Pharm., 1983; 9: 602-25.
38. Keith, A.D. and Snipes, W., Polymeric diffusion matrix containing proparanol, U.S. Pat. 4, US4292302A, 1984; 460-562.
39. Keith, A.D., Trinitroglycerol Sustained Release Vehicles and Preperation of thereform, U.S. Patent 4, WO1983000093A1, 1985; 542: 013.
40. Khandelwal K.R., Practical pharmacognosy, Nirali prakashan, Pune, 12th edition, 2003; 149.